Implementing patient-reported outcome measures on an adolescent inpatient psychiatry unit: A feasibility study.
Carl WaitzAnnmarie CaracansiKaty KaufmanEmily CampbellEthan AnglemyerYohanis Anglero-DiazSherry PadenBilly ZouPatricia IbeziakoPublished in: Psychological services (2024)
This article examines the feasibility of implementing patient-reported outcome (PRO) measures with adolescents on an inpatient psychiatry service. During the study period (March 8, 2021, to June 7, 2022), a total of 154 patient encounters were recorded for adolescents between 12 and 17 years of age. PROs were piloted during the first 3 months of the study period, with a focus on technical implementation. In the 12 months from June 8, 2021, through June 7, 2022, the PRO project moved to full implementation across all patient encounters. Fisher's exact test and independent t tests were conducted to examine the differences between patients who completed the PROs and patients who did not complete them to determine the representativeness of the sample receiving them. During the 3-month pilot period, 31.8% of patients completed the PROs at admission and discharge, while during the 12-month full implementation, 74.5% of patients completed them at both time points. Statistical tests showed no significant diagnostic, sex, or race/ethnicity differences between patients who received and did not receive the outcome measures. Even without funding, small inpatient psychiatry services for adolescents can feasibly implement PROs with completion rates similar to other published studies and capture the majority of the patients served. (PsycInfo Database Record (c) 2024 APA, all rights reserved).
Keyphrases
- patient reported outcomes
- end stage renal disease
- mental health
- young adults
- healthcare
- chronic kidney disease
- ejection fraction
- primary care
- quality improvement
- newly diagnosed
- physical activity
- prognostic factors
- peritoneal dialysis
- emergency department
- systematic review
- case report
- clinical trial
- patient reported
- adverse drug
- double blind